EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial

Mixue Xie, Ying Lu, Guifang Ouyang, Xueying Li iD, Ting Shi, Min Yang, Jing Le, Huixian Hu, Li Zhang, Weiying Feng, Haitao Meng, Wenyuan Mai und 18 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18975 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Mixue Xie und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To reducing chemotherapy‐related toxicity, the chemo‐free regimens become a new trend of Ph + ALL treatment. Therefore, we conducted a phase 2 trial of dasatinib plus prednisone, as induction (Course I) and early consolidation (Courses II and III) treating newly diagnosed Ph + ALL. The trial was registered at www.chictr.org.cn , ChiCTR2000038053. Forty‐one patients were enrolled from 15 hospitals. The complete remission (CR) was 95% (39/41), including two elderly induction deaths. By the end of Course III, 25.6% (10/39) of patients achieved a complete molecular response. With a median follow‐up of 15.4 months, 2‐year disease‐free survival (DFS) were 100% and 33% for patients who receiving haematopoietic stem cell transplantation (HSCT) at CR1 and receiving chemotherapy alone respectively. When censored at time of HSCT, 2‐year DFS were 51% and 45% for young and elderly patients ( p = 0.987). 2‐year overall survival were 45%, 86% and 100% for patients without HSCT, receiving HSCT after relapse and receiving HSCT at CR1 respectively. A total of 12 patients had marrow recurrences and one had CNS relapse, with 38% occurred early (between Courses I and III). IKZF1 gene deletion was shown to be associated with relapse ( p = 0.019). This chemo‐free induction and early consolidation regimen was efficacious and well‐tolerated in de novo Ph + ALL. Allogeneic HSCT conferred definite survival advantage after chemo‐free induction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationHumansAdultAgedDasatinibPrednisonePhiladelphia ChromosomeNeoplasm Recurrence, LocalDisease-Free SurvivalRemission InductionAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Ph-positive ALLchemo-freetyrosine kinase inhibitor

Substanzen

DasatinibPrednisone

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China.
  • Department of Hematology, Ningbo Hospital of Zhejiang University, Ningbo, China.
  • Department of Hematology, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
  • Department of Hematology, Jinhua Municipal Central Hospital Medical Group, Jinhua, China.
  • Department of Hematology, Taizhou Hospital of Zhejiang Province, Taizhou, China.

ORCID-Profile: Xueying Li, Hongyan Tong, Hong-Hu Zhu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Xie, M., Lu, Y., Ouyang, G., Li, X., Shi, T., Yang, M., Le, J., Hu, H., Zhang, L., Feng, W., Meng, H., Mai, W., Wei, J., Qian, J., Xu, G., Yang, C., Zhou, Lin, Y., Qian, S., …, & Zhu, H. H. (2023). Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial. British Journal of Haematology. https://doi.org/10.1111/bjh.18975

Vancouver

Xie M, Lu Y, Ouyang G, Li X, Shi T, Yang M, et al. Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial. British Journal of Haematology. 2023. doi:10.1111/bjh.18975

BibTeX
@article{Xie2023,
  author = {Xie, Mixue and Lu, Ying and Ouyang, Guifang and Li, Xueying and Shi, Ting and Yang, Min and Le, Jing and Hu, Huixian and Zhang, Li and Feng, Weiying and Meng, Haitao and Mai, Wenyuan and Wei, Juying and Qian, Jiejing and Xu, Gaixiang and Yang, Chunmei and Zhou, De and Lin, Yin and Qian, Suying and Kuang, Yuemin and Zhang, Liming and Zhu, Weiguo and Yao, Guoli and Wu, Gongqiang and Hu, Shao and Huang, Xin and Wang, Yungui and Tong, Hongyan and Jin, Jie and Zhu, Hong-Hu},
  title = {Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18975}
}
Kostenlos starten →